No Stock Yet
Sector Update: Health Care Stocks Declines Wednesday Afternoon
01:29 PM EDT, 03/22/2023 (MT Newswires) -- Health care stocks were declining Wednesday afternoon, with the NYSE Health Care Index falling 0.3%, the Health Care Select Sector SPDR Fund (XLV) down 0.4%,
Panbela Therapeutics Secures Patent in Japan; Shares Rise
12:01 PM EDT, 03/22/2023 (MT Newswires) -- Panbela Therapeutics (PBLA) said Wednesday it secured a patent in Japan covering a process with a reduced number of synthetic steps to produce SBP-101, a lea
Panbela Announces Issuance Of New Patent In Japan; Patent Is For Claims Of A Novel Process For The Production Of SBP-101
Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification
Maxim Group Upgrades Panbela Therapeutics to Buy, Announces $1.5 Price Target
Maxim Group analyst Jason McCarthy upgrades Panbela Therapeutics from Hold to Buy and announces $1.5 price target.
Panbela Therapeutics Upgraded to Buy From Hold at Maxim Group
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2022 Earnings Call Transcript
Panbela Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q4 EPS Results.
Panbela Therapeutics shares are trading lower after the company reported worse-than-expected Q4 EPS results.
Q4 2022 Panbela Therapeutics Inc Earnings Call
Panbela Therapeutics Q4 EPS $(5.68) Misses $(3.70) Estimate
Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(5.68) per share which missed the analyst consensus estimate of $(3.70) by 53.51 percent. This is a 45.38 percent increase over losses
Earnings Scheduled For March 16, 2023
Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million. • ImmunoPrecise Antibodies (NASDAQ:IPA) is
No Stock Yet